Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IDEC-Y2B8

A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. IDEC-Y2B8 contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. IDEC-Y2B8 is a type of radioimmunoconjugate. Also called 90Y-ibritumomab tiuxetan, 90Y-Zevalin, and yttrium Y 90-ibritumomab tiuxetan.

IDEC-Y2B8

Search NCI's Dictionary of Cancer Terms